Sonography of the Optic Nerve Sheath Diameter for Detection of Elevated Intracranial Pressure (ICP)

February 25, 2020 updated by: Islam Hassan Mohamed Elsadek Abulnaga, National Heart Institute, Egypt

Sonography of the Optic Nerve Sheath Diameter for Detection of Elevated Intracranial Pressure Compared to Computed Tomography

In this study the invistigators chose to measure the optic nerve sheath diameter by sonography for diagnosis of elevated intracranial pressure (ICP) in comparison to brain computed tomograhy (CT) as the reference gold standard for detection of raised ICP since optic nerve songraphy is radiation-free , noninvasive, and has certain features which increase its convenience portability, easy application, low cost, repeatability on request, bedside application, short application time and applicability even in the presence of unstable vital signs.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Elevated intracranial pressure (ICP) is seen in head trauma, hydrocephalus, intracranial tumors, hepatic encephalopathy, and cerebral edema. Intractable elevated ICP can lead to death or devastating neurological damage either by reducing cerebral perfusion pressure (CPP) and causing cerebral ischemia or by compressing and causing herniation of the brainstem or other vital structures. Prompt recognition is crucial in order to intervene appropriately.

Intractable high ICP is the most common "terminal event" leading to death in neurosurgical patients. The association between the severity of intracranial hypertension and poor outcome after severe head injury is well recognized. Outcomes tend to be good in patients with normal ICP, whereas those with elevated ICP are much more likely to have an unfavorable outcome. Elevated ICP carries a mortality rate of around 20%.

The rapid recognition of elevated ICP is therefore of obvious and paramount importance so that it can be monitored and so that therapies directed at lowering ICP can be initiated. A raised ICP is measurable both clinically and quantitatively. Continuous ICP monitoring is important both for assessing the efficacy of therapeutic measures and for evaluating the evolution of brain injury.

The goal of ICP monitoring is to ensure maintenance of optimal CPP. The ICP also forms a basis for medical or surgical intervention in cases of increased ICP with agents such as 3% sodium chloride (NaCl), mannitol, or diuretics (Loop diuretics), ventriculostomy, cerebrospinal fluid (CSF) diversion, and phentobarbital coma or surgical decompression in cases of intractable ICP elevation that do not respond to conservative management.

ICP monitoring may be discontinued when the ICP remains in the normal range within 48-72 hours of withdrawal of ICP therapy or if the patient's neurological condition improves to the point where he or she is following commands.

Since many investigators have questioned invasive ICP monitoring in improving patient outcomes, the invistigators tried to find noninvasive method of ICP monitoring.

The optic nerve sheath is contiguous with the dura mater, and its contents are contiguous with the subarachnoid space. Thus, raised intracranial pressure (ICP) leads to an increase in the optic nerve sheath diameter.

A-mode sonography was first used for visualization of the optic nerve sheath; however, it was not until 1994, when Hansen et al used B-mode sonography, when the approach to measurement was standardized. Sonographic studies of cadaveric optic nerves together with the work of Hansen et al established that the greatest degree of distension of the sheath occurred 3 mm behind the optic globe. This location has become the standard measurement point.

As a technique, ocular sonography is quickly learned; Tayal et al showed that with an experienced operator, 10 scans with 3 abnormal scans should be sufficient training, whereas in new ultrasound operators, 25 may be needed. In addition to these findings, measurement of both eyes can be performed in less than 4 minutes.

the invistigators chose CT as the reference gold standard for detection of raised ICP as simple noninvasive method in critically ill patients. Raised ICP is diagnosed with CT on a daily basis in clinical practice. Treatments are initiated, hemicraniectomies are performed, and intraventricular shunts are inserted, all on the basis of raised ICP as seen on imaging.

The findings of elevated ICP in cranial CT (CCT) include:

  1. changes in ventricular sizes;
  2. lessening in basilar cistern sizes;
  3. narrowing or eliminating in sulci;
  4. transfalcine herniation; and
  5. changes in the rate of grey/white matter. So in this study the invistigators chose to measure optic nerve sheath diameter by sonography for diagnosis of elevated ICP in comparison to brain CT as the reference gold standard for detection of raised ICP

Study Type

Observational

Enrollment (Actual)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Cairo, Egypt, 12345
        • National heart institute , Imbaba

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

100 adult patients with clinically suspected raised ICP such as:

  1. Patients with traumatic brain injury
  2. Patients with intracranial tumours
  3. Patients with hepatic encephalopathy
  4. Cerebral edema: Due to head injury, ischemic stroke with vasogenic edema, hypoxic or ischemic encephalopathy, postoperative edema

Description

Inclusion Criteria:

  • Patients with clinically suspected raised ICP such as:

    1. Patients with traumatic brain injury
    2. Patients with intracranial tumours
    3. Patients with hepatic encephalopathy
    4. Cerebral edema: Due to head injury, ischemic stroke with vasogenic edema, hypoxic or ischemic encephalopathy, postoperative edema

Exclusion Criteria:

  • Patients with edema or trauma in the eye lid.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To measure the optic nerve sheath diameter by optic nerve ultrasound in patients with elevated ICP before and after osmotherapy and to measure the accuracy of occular ultrasound in diagnosis of elevated ICP compared to cranial computed tomography (CT)
Time Frame: up to 48 hours
Cranial CT and optic nerve US will be done once elevated ICP is suspected clinically to find signs of elevated ICP in cranial CT and measure the optic nerve sheath diameter by optic nerve ultrasound and then follow up optic nerve sonograhy and cranial CT will be done after 48 hours of giving osmotheray to detect the effect of osmotherapy on signs of elevated ICP in cranial CT and on the optic nerve sheath diameter
up to 48 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Mohamed H Abdallah, MD, Cairo University
  • Study Director: Suzy F Michael, MD, Cairo University
  • Study Director: Hassan K Nagi, MD, Cairo University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2017

Primary Completion (Actual)

July 1, 2018

Study Completion (Actual)

October 1, 2019

Study Registration Dates

First Submitted

May 7, 2018

First Submitted That Met QC Criteria

May 7, 2018

First Posted (Actual)

May 18, 2018

Study Record Updates

Last Update Posted (Actual)

February 27, 2020

Last Update Submitted That Met QC Criteria

February 25, 2020

Last Verified

February 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • Optic nerve sonography and ICP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Intracranial Hypertension

Clinical Trials on optic nerve ultrasound

3
Subscribe